A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers
Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, phase II, open label study of apatinib mesylate tablets plus
tegafur gimeracil oteracil potassium capsules in recurrent/metastatic squamous cell carcinoma
of head and neck. The primary purpose of this study is to evaluate the efficacy of apatinib
mesylate tablets plus tegafur gimeracil oteracil potassium capsules in recurrent/metastatic
squamous cell carcinoma of head and neck
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University